The selected BCL-xL inhibitors include ABT-199 (VenclextaTM, Venclyxto, Venetoclax), an FDA-approved compound for the treatment of leukaemia, and ABT-263 (Navitoclax), a compound currently in phase I/II clinical trials for the treatment of lymphoid malignancies. Here, BCL2L1 is linked to leukemia.